With nod, Roche's Kadcyla should quickly become blockbuster

At an earnings call last month, Roche ($RHHBY) CEO Severin Schwan crowed a bit about the Swiss company's future, pointing to drugs in the pipeline like its highly anticipated breast cancer treatment and potential blockbuster T-DM1. Today, the FDA gave approval to the drug, which will be marketed as Kadcyla, for patients with HER2-positive, late-stage (metastatic) breast cancer. The drug will have an estimated monthly cost of $9,800, or about $94,000 for a full course of treatments, Forbes reports. As FierceBiotech points out, forecasts have put peak sales of the breakthrough antibody drug conjugate at between $2 billion and $5 billion. Roche has reported that in a Phase III study, the drug reduced the risk of death among patients by 32% compared to the standard-of-care arm. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.